Susquehanna International Group LLP Buys 31,148 Shares of Electromed, Inc. (NYSE:ELMD)

Susquehanna International Group LLP raised its stake in Electromed, Inc. (NYSE:ELMD) by 121.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,726 shares of the company’s stock after acquiring an additional 31,148 shares during the quarter. Susquehanna International Group LLP owned about 0.66% of Electromed worth $1,676,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ELMD. Aristides Capital LLC lifted its position in Electromed by 4.7% during the 4th quarter. Aristides Capital LLC now owns 26,076 shares of the company’s stock valued at $771,000 after purchasing an additional 1,159 shares during the period. Russell Investments Group Ltd. bought a new position in Electromed in the fourth quarter valued at approximately $37,000. IFP Advisors Inc acquired a new stake in Electromed during the 4th quarter worth $59,000. Barclays PLC lifted its stake in shares of Electromed by 25.0% in the 4th quarter. Barclays PLC now owns 12,529 shares of the company’s stock valued at $371,000 after purchasing an additional 2,507 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Electromed in the 4th quarter valued at $99,000. 40.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. B. Riley started coverage on Electromed in a report on Thursday, February 20th. They issued a “buy” rating and a $38.00 price objective for the company. StockNews.com downgraded Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

Electromed Price Performance

NYSE:ELMD opened at $22.20 on Monday. The business’s 50-day simple moving average is $23.51 and its 200-day simple moving average is $27.38. Electromed, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $35.56. The stock has a market capitalization of $189.97 million, a PE ratio of 29.60 and a beta of 0.46.

Electromed announced that its board has approved a stock buyback plan on Monday, March 10th that permits the company to repurchase $5.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Insider Activity

In related news, Director Andrew Summers sold 50,751 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.30, for a total value of $1,385,502.30. Following the sale, the director now directly owns 65,714 shares of the company’s stock, valued at approximately $1,793,992.20. The trade was a 43.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kathleen Skarvan sold 8,640 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $32.25, for a total transaction of $278,640.00. Following the completion of the transaction, the director now directly owns 71,576 shares of the company’s stock, valued at approximately $2,308,326. The trade was a 10.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 133,618 shares of company stock worth $3,821,636 over the last quarter. 14.00% of the stock is currently owned by company insiders.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.